This article is more than 5 years old. Information may no longer be current.

Glaukos raises $30 million to fund iStent launch in US, further studies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Glaukos closed $30 million in Series F financing to pay for the commercial launch of the iStent trabecular micro-bypass device in the United States, according to a company news release.

The funds also will be used for investigational device exemption pivotal registration studies of iStent supra, a suprachoroidal implant, and iStent inject, a second-generation trabecular bypass implant.

The iStent was approved by the U.S. Food and Drug Administration in June 2012.

Meritech Capital Partners led the financing round. Other investors included Versant Ventures, Domain Associates, Montreux Equity Partners, InterWest Partners, Frazier Healthcare, OrbiMed Advisors and Gund Investment Corporation.